1-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-one | 23982-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-one
• 英文别名: N-1,2,3,4-Tetrahydroisochinolinylaceton；1-(3,4-dihydro-1H-isoquinolin-2-yl)propan-2-one
• CAS: 23982-55-0
• 化学式: C₁₂H₁₅NO
• mdl: MFCD08059714
• 分子量: 189.257
• InChiKey: DYZHQYKGPCKCDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-苯基马来酰亚胺 、 1-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-one 在 chlorophyll a 、 氧气 作用下， 以 甲苯 为溶剂， 反应 30.0h， 以90%的产率得到
  参考文献：
  名称：

  叶绿素催化串联氧化/ [3 + 2]环加成反应在可见光下对吡咯并[2,1-a]异喹啉的构建

  摘要：

  叶绿素是一种绿色，廉价且可负担的天然色素，用于在可见光下一锅合成吡咯并[2,1-a]异喹啉骨架。这种光催化方法已经使用空气作为最终氧化剂处理了氧化/ [3 + 2]环加成/芳构化的级联反应。在这种条件下，用双极性亲和剂以良好至优异的产率处理了各种N-取代的四氢异喹啉。

  DOI：

  10.1016/j.jphotochem.2020.112877
• 作为产物：
  描述：

  四氢异喹啉 、 2-(三甲基硅氧基)丙烯 在 lithium perchlorate 、 sodium iodide 作用下， 以 乙腈 为溶剂， 以82%的产率得到1-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-one
  参考文献：
  名称：

  甲硅烷基烯醇醚的上位电，碘介导的酮的α-CH胺化。

  摘要：

  描述了利用简单的碘盐合成的α-氨基酮的甲硅烷基烯醇醚的电化学氧化Umpolung反应。分离出的产物的收率高达100％，且功能齐全的起始材料已被接受用于未拆分的电化学电池设计中。此外，为了确保反应的再现性得到改善，进行了敏感性评估，并进行了循环伏安法实验，以根据其基础推测出合理的反应机理。

  DOI：

  10.1021/acs.orglett.0c02068

文献信息

• Glycerol as a Building Block for Prochiral Aminoketone,<i>N</i>-Formamide, and<i>N</i>-Methyl Amine Synthesis
  作者：Xingchao Dai、Jabor Rabeah、Hangkong Yuan、Angelika Brückner、Xinjiang Cui、Feng Shi

  DOI：10.1002/cssc.201600972

  日期：2016.11.23

  Prochiral aminoketones are key intermediates for the synthesis of optically active amino alcohols, and glycerol is one of the main biomass‐based alcohols available in industry. In this work, glycerol was catalytically activated and purposefully converted with amines to generate highly valuable prochiral aminoketones, as well as N‐formamides and N‐methyl amines, over CuNiAlOx catalyst. The catalyst structure

  前手性氨基酮是光学活性氨基醇合成的关键中间体，甘油是工业上可用的主要基于生物质的醇之一。在这项工作中，甘油在CuNiAlO x催化剂上被催化活化，并有意地与胺转化生成高度有价值的前手性氨基酮，以及N-甲酰胺和N-甲基胺。通过形成纳米Cu-Ni合金颗粒，可以将催化剂结构预期为CuAlO x之上或之中的纳米Ni物种。这个概念可能会提出一种新颖而有价值的甘油利用方法。
• Dual organic dyes as a pseudo-redox mediation system to promotion of tandem oxidation /[3+2] cycloaddition reactions under visible light
  作者：Mehdi Koohgard、Zeinab Hosseinpour、Mona Hosseini-Sarvari

  DOI：10.1016/j.tet.2021.132166

  日期：2021.6

  treated with in situ generated azomethine ylides to prepare corresponding products in good to excellent yields. This metal-free method effectively promoted oxidation/[3 + 2] cycloaddition/oxidative/aromatization domino reaction without further oxidant using dual organic dyes as pseudo-redox mediation system. Besides, for most of the products, product precipitate was readily separated from reaction media

  已经开发了一种原子经济和阶梯经济协议，以在可见光照射下通过氧化还原介导系统合成一些新的生物活性吡咯并[2,1- a ]异喹啉生物碱。各种各样的双键和三键，作为偶极体，用原位生成的偶氮甲碱叶立德处理以制备相应的产品，产率很好。这种不含金属的方法使用双有机染料作为假氧化还原介导系统，有效地促进了氧化/[3+2]环加成/氧化/芳构化多米诺反应，无需进一步的氧化剂。此外，对于大多数产物，产物沉淀很容易从反应介质中分离出来。据我们所知，这是双染料作为伪氧化还原介导系统的第一份报告.
• Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl
  申请人：Kikuchi Kazumi

  公开号：US20070099956A1

  公开（公告）日：2007-05-03

  The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.

  本发明提供了一种新型含氮杂环衍生物，其具有2,6-二取代苯乙烯基和其药学上可接受的盐，以及包括该含氮杂环衍生物和其药学上可接受的盐的药物组合物，特别是一种有效的钠通道抑制剂药物组合物，对于神经病理性疼痛具有出色的镇痛作用，并最小化副作用。
• MOEHRLE H.; GRIMM B., ARCH. PHARM., 319,(1986) N 9, 774-787
  作者：MOEHRLE H.、 GRIMM B.

  DOI：——

  日期：——
• COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS
  申请人：Boeckler Frank

  公开号：US20110059953A1

  公开（公告）日：2011-03-10

  Compounds of formula (I): wherein X is selected from CR X and N; R N1 is selected from H and C 1-4 alkyl, which may be substituted by SH or halo; R G1 is selected from H and SH; R C2 is selected from H and optionally substituted C 1-7 alkyl; R C3 is selected from H and optionally substituted C 1-7 alkyl; R x is selected from H, OH and NH 2 ; R C4 is selected from: (i) an optionally substituted C 3-12 N-containing heterocyclyl; (ii) C(═O)NR N5 R N6 , where R N5 and R N6 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or RN5 and RN6 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group; (iii) C(═O)OR O1 , where R O1 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (iv) C(═O)NHNHSO 2 R S1 , where R S1 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (v) OC(═O)RC8, where RC8 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (vi) OC(═O)NR N7 R N8 , where R N7 and R N8 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or R N7 and R N8 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group; and (vii) C(═O)CH 2 NH C(═O)NHNH 2 , CHC(CN) 2 , CHC(CN)C(═O)NH 2 , and carboxy; R C5 is selected from H, OH and NH 2 ; or R C4 and R C5 together with the carbon atoms to which they are bound form an optionally substituted aromatic ring containing either 5 or 6 ring atoms, of formula: where Q represents O, N, or CR Q1 ═CR Q2 , where R Q1 and R Q2 are independently selected from H, OH and NH 2 ; R C6 is selected from H, OH and NH 2 ; and R C7 is selected from optionally substituted C3_12 N-containing heterocyclyl, NHC(═O)R C9 , CH 2 NR N2 R N3 and NHC(═S)NHR N4 , where R C9 is selected from optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl, R N2 and R N3 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or R N2 and R N3 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group, and R N4 is selected from optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl, and when R C4 and R C5 are not bound together, R C3 may additionally be selected from OR 02 , where R O2 is a C 1-4 alkyl group, and C(═O)OR O3 , where R O3 is a C 1-4 alkyl group and R C2 may additionally be selected from halo, for use in stabilising a p53 protein carrying a Y220C mutation.